VIENNA, Va., Jan. 28 /PRNewswire-FirstCall/ -- The following letter is
being released by CEL-SCI CORPORATION (Amex: CVM) to its shareholders:
Dear Fellow Shareholders:
Our Company underwent a wonderful transformation last year from an
intermediate stage company in its development to a late-stage biotechnology
company. We are now one of a very select number of companies that have a
completely novel medicine with blockbuster potential ready to go into a
Phase III clinical trial. Our position is further enhanced by the fact that
we are well capitalized and that we are building our own manufacturing
facility close to Baltimore, Maryland. This facility will be capable of
producing between $500 million and $600 million worth of Multikine(R)
cancer drug per year, with the ability to triple production within about
one year. The construction of the facility is scheduled for completion in
the 3rd quarter of 2008.
Company highlights of 2007:
-- FDA clearance of Multikine for Phase III clinical trial in head and
neck cancer
-- Raised U.S. $15 million
-- Multikine granted Orphan drug designation in U.S.
-- Started build-out of manufacturing facility for Multikine to support
upcoming Phase III study and commercial sale
-- Started planning and pricing of our global clinical trial designed to
lead to marketing approval for Multikine
We expect 2008 to be another very positive year. We plan to contract
with one or more Clinical Research Organizations to run our 800 patient
Multikine Phase III trial which we expect to start in the last quarter of
2008. It will be run as an open label study (a study in which it is
apparent which patients receive Multikine versus those who do not). The
open label design will give us the opportunity to get early indications of
how successful our study will be.
We look forward to moving into the new facility later this year and we
anxiously await the first indications from the open-label Phase III
clinical trial with Multikine in advanced primary (not yet treated) head
and neck cancer, representing a large unmet medical need and a disease in
dire need of new and non-toxic treatments.
Thank you for your continued support. We invite you to visit our new
website at http://www.cel-sci.com to learn more about our breakthrough work in
empowering immune defenses to defeat cancer.
Sincerely yours,
Geert Kersten Maximilian de Clara
Chief Executive Officer President
When used in this report, the words "intends," "believes,"
"anticipated" and "expects" and similar expressions are intended to
identify forward-looking statements. Such statements are subject to risks
and uncertainties which could cause actual results to differ materially
from those projected. Factors that could cause or contribute to such
differences include, an inability to duplicate the clinical results
demonstrated in clinical studies, timely development of any potential
products that can be shown to be safe and effective, receiving necessary
regulatory approvals, difficulties in manufacturing any of the Company's
potential products, inability to raise the necessary capital and the risk
factors set forth from time to time in CEL-SCI Corporation's SEC filings,
including but not limited to its report on Form 10- K for the year ended
September 30, 2007. The Company undertakes no obligation to publicly
release the result of any revision to these forward-looking statements
which may be made to reflect the events or circumstances after the date
hereof or to reflect the occurrence of unanticipated events.
SOURCE CEL-SCI Corporation
 back to top
Related links:
http://www.cel-sci.com
CONTACT:
Gavin de Windt of CEL-SCI Corporation,
+1-703-506-9460
|
